Top Markets
Coin of the day
Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

NLTX
주식 순위 #26679
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused... Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
주가
$3.49
마지막 동기화: 2023-12-19
시가총액
$38.68M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Neoleukin Therapeutics, Inc. (NLTX)

카테고리

Neoleukin Therapeutics, Inc. (NLTX)의 EPS
2026 기준 EPS TTM: 0
Neoleukin Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Neoleukin Therapeutics, Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.